OGN · XBRL financial data

Organon financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OGN's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	6,304	6,174	6,263	6,403	6,216
Cost of goods and services sold	2,382	2,294	2,515	2,688	2,903
Gross profit	—	3,880	3,748	3,715	3,313
Research and development	443	—	—	—	—
Selling, general and administrative	1,668	1,704	1,893	1,760	1,721
Interest expense	258	422	527	520	504
Income tax expense (benefit)	178	205	(350)	(57)	238
Net income (loss)	1,351	917	1,023	864	187
Earnings per share, basic USD per share	5.33	3.61	4.01	3.36	0.72
Earnings per share, diluted USD per share	5.31	3.59	3.99	3.33	0.72
Weighted average shares, basic millions of shares	254	254	255	257	259
Weighted average shares, diluted millions of shares	254	255	256	259	261

Fiscal years (OGN's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	737	706	693	675	574
Accounts receivable	1,382	1,475	1,744	1,358	1,331
Inventory	915	1,003	1,315	1,321	1,406
Total current assets	3,760	3,931	4,508	4,348	4,352
Property and equipment, net	973	1,018	1,183	1,168	1,303
Right-of-use asset	230	215	173	157	155
Goodwill	4,603	4,603	4,603	4,680	4,153
Total assets	10,681	10,955	12,058	13,101	12,867
Accounts payable	1,382	1,132	1,314	1,153	952
Current portion of long-term debt	9	8	9	20	—
Total current liabilities	2,597	2,512	2,918	2,718	2,390
Long-term debt	9,125	8,905	8,751	8,860	8,628
Lease liability, non-current	184	150	125	112	116
Total liabilities	—	11,847	12,128	12,629	12,115
Retained earnings (accumulated deficit)	(998)	(331)	443	1,010	1,109
Total stockholders' equity	(1,508)	(892)	(70)	472	752
Total liabilities and equity	10,681	10,955	12,058	13,101	12,867
Common shares outstanding (cover page) millions of shares	254	254	256	258	260

Fiscal years (OGN's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,351	917	1,023	864	187
Stock-based compensation	59	75	101	105	77
Net cash from operating activities	—	858	799	939	700
Purchases of property and equipment	192	196	251	175	162
Net cash from investing activities	—	(420)	(260)	(513)	(390)
Dividends paid	145	290	294	297	88
Proceeds from long-term debt	9,470	0	80	1,186	1,055
Repayments of long-term debt	112	108	338	1,197	1,513
Net cash from financing activities	—	(433)	(569)	(368)	(561)
Net change in cash	667	(31)	(13)	(18)	(101)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Organon	1,455	1,574	370*	262.6M	—	Q3 FY26 10-QSep 30, 2026
Cytokinetics	203	48	(124)*	139.3M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Summit Therapeutics	151	not reported	(160)*	799.8M	4.5 quarters	Q3 FY26 10-QSep 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	322	342	12*	172.8M	—	Q3 FY26 10-QSep 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 2:03 AM ET. The filing on SEC.gov is the record.